Citius Oncology reports 120% jump in LYMPHIR wholesaler unit sales for fiscal Q4 2026
Preliminary, unaudited figures show 792 units sold to U.S. wholesalers in the quarter ended September 30, 2026, up from 360 in the prior quarter, with institutional adoption also rising.
Citius Oncology, Inc. (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), disclosed preliminary unit sales figures for LYMPHIR (denileukin diftitox-cxdl) on October 26, 2026, covering its fiscal fourth quarter ended September 30, 2026.
The company reported 792 units purchased by U.S. wholesalers for the three months ended September 30, 2026, compared to 360 units for the three months ended June 30, 2026, an increase of 120%, and 950 LYMPHIR vials ordered by prescribing centers from wholesalers during the fiscal fourth quarter, compared to 926 for the fiscal third quarter.1 The company also said as of the date of the release, 54 institutions had ordered LYMPHIR, compared to 44 as of August 14, 2026, as last reported.1
Chairman and CEO Leonard Mazur attributed the increase to expanded commercial reach, saying the fiscal fourth quarter showed continued institutional demand for LYMPHIR, with unit sales to wholesalers more than doubling as the expanded commercial team reached nationwide coverage in August.1 He added that the company is more than halfway to its goal of having LYMPHIR on formulary at 100 priority institutions by calendar year-end.1
The release noted that these figures are preliminary: the unit information is unaudited, based on management's current estimates, and subject to completion of year-end closing procedures and the audit of fiscal 2026 financial statements, and the company's independent registered public accounting firm has not audited, reviewed, or performed any procedures on the figures.1 The company clarified that it recognizes revenue when wholesaler orders are fulfilled, so reported revenue reflects units sold to wholesalers rather than institutional vial orders.1 Full fiscal fourth quarter and fiscal year 2026 results are expected with the company's upcoming annual report filing in December 2026.
LYMPHIR is described as a targeted immunotherapy for relapsed or refractory cutaneous T-cell lymphoma indicated for Stage I–III disease after at least one prior systemic therapy, a recombinant fusion protein combining the IL-2 receptor binding domain with diphtheria toxin fragments that binds IL-2 receptors on cell surfaces and causes cell death.1 It was approved by the FDA and launched in the U.S. in December 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.